[Form 4] BridgeBio Pharma, Inc. Insider Trading Activity

Rhea-AI Filing Summary

On 06/27/2025, BridgeBio Pharma, Inc. (BBIO) director Charles J. Homcy, M.D. filed a Form 4 reporting a bona-fide gift of 20,000 common shares. Coded "G", the transaction involved no cash consideration and therefore carries limited price-discovery value. After the transfer, Homcy still owns 1,216,674 shares directly, reducing his stake by roughly 1.6% and leaving BridgeBio’s share count effectively unchanged. The filing appears routine and does not affect the company’s fundamentals or near-term liquidity.

Insights

Portfolio Manager

TL;DR: Routine gift; negligible ownership change; neutral market impact.

The 20,000-share transfer is classed as a gift (code G), meaning no shares were sold for cash. With only a 1.6% reduction in Dr. Homcy’s personal holdings and an immaterial effect on BridgeBio’s float, the event does not signal dissatisfaction or financial stress. Homcy’s remaining 1.2 million-plus shares maintain strong alignment with other shareholders. I view the disclosure as non-impactful for valuation or trading dynamics.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HOMCY CHARLES J

(Last) (First) (Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/27/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/27/2025		G		20,000	D	$0	1,216,674	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Charles J. Homcy, M.D.	06/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many BBIO shares did Charles J. Homcy transfer on 06/27/2025?

20,000 common shares were transferred.

What does transaction code "G" mean in the Form 4 for BBIO?

Code "G" denotes a bona-fide gift, indicating no cash consideration.

How many BBIO shares does Homcy own after the reported transaction?

He beneficially owns 1,216,674 shares directly after the gift.

Was any cash exchanged for the shares gifted by Homcy?

No. The gift was reported at $0 per share with no cash involved.

Does the Form 4 filing indicate use of a Rule 10b5-1 trading plan?

The filing does not indicate that the transaction was executed under a Rule 10b5-1 plan.